沙美特罗替卡松治疗特发性肺间质纤维化的临床观察

Clinical effect of salmeterol-fluticasone on idiopathic pulmonary fibrosis

目的探讨沙美特罗替卡松对特发性肺间质纤维化(IPF)的治疗效果。方法 68例IPF患者分为对照组和治疗组,分别接受波尼松和沙美特罗替卡松治疗12周;比较治疗后两组患者临床症状、高分辨率CT(HRCT)计分以及肺功能的改变。结果治疗组患者吸入沙美特罗替卡松粉剂后,临床症状改善情况优于对照组;高分辨CT肺部扫描提示治疗组总有效率为80%,而对照组总有效率为65%;治疗组患者肺功能各项指标的改善情况也优于对照组患者。结论沙美特罗替卡松不仅能有效控制IPF患者的临床症状,同时也降低了糖皮质激素的用量。

【Objective】 To investigate the effects of salmeterol-fluticasone（SF） on idiopathic pulmonary fibrosis（IPF）.【Methods】 68 IPF patients were assigned into control group and SF group treated with prednisone and SF for 12 weeks,respectively;Comparing the changes of clinical symptoms,HRCTR and pulmonary functions between control group and SF group.【Results】 The effects of salmeterol-fluticasone（SF） on IPF were better prednisone;HRCT results indicated that total effectiveness ration of SF group was 80%,which of control group was 65%;Pulmonary function indexes of SF group were better than control group.【Conclusion】 SF could not only control clinical symptoms of IPF patients,but lower the dose of glucocorticoid.